Welcome to our inaugural June 2022 Newsletter! Your information source for news, updates, and events (past and future). We are grateful to the CELS community for joining us. |
|
|
CELS is a not for profit association supporting the advancement of innovative Canadian Life Science businesses in the San Francisco Bay Area and Silicon Valley through the power of the power of Community and Connections.
|
If you would like to contribute to the newsletter, provide feedback or seek CELS membership info please email us at info@cels-sfo.com
|
|
|
|
|
|
|
June 13-16, 2022 San Diego, CA |
|
BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. Click here to know more!
|
|
|
|
|
June 20-23, 2022 Toronto, ON |
|
With over 400+ speakers, 1250+ startups, 200+ partners, 800+ investors , and over 33000 attendees, Collision is the 'OLYMPICS OF TECH'. Click here for details!
|
|
|
|
|
July 02, 2022 Woodside, CA |
|
It’s back! the annual Digital Moose Lounge Canada Day Picnic, after a 2-year hiatus, bringing together Bay Area Canadians in a social setting to celebrate Canada. Meet new #sfbaycanadians and reconnect with old friends while celebrating Canada Day!
The picnic brings together our local diverse community from the consulate, business, culture, sports, and entertainment. And visiting Canadians are welcome. To learn more and register, click here!
CELS is proud to be partners with The Digital Moose Lounge, a long-standing social community of Canadians in the San Francisco Bay Area. |
|
|
|
|
|
|
Featuring Canadian Life Science companies in the Spring 2022 Cohort of the CELS Valley Ready (VR) program. For more info on the CELS VR program click here!
|
|
|
|
|
|
|
|
|
Did you know that eight out of 10 people go on the Web to get health information? Yet almost 2 out of 3 healthcare companies on the Fortune 1000 list have limited health content or none on their site.
Factually Health is developing an AI-platform, scalable to any disease, to build tools for health companies, tools they can share with their patients, to engage and empower them.
We are starting with women’s health (cancer), COVID-19, and diabetes and will be expanding to other disease states in the future. Factually Health is next-level health intelligence for companies and their patients. Read more here! |
|
|
|
Soricimed Biopharma Inc. is a clinical stage company focused on developing better, first-in-class targeted therapeutics for several common solid tumor cancers. Based in Moncton, New Brunswick, Soricimed was established following the discovery of a unique and proprietary family of paralytic and anti-cancer peptides found in the venom of the northern short-tailed shrew. This discovery led the Company to develop a novel platform of proprietary, synthetic peptides that target the TRPV6 calcium ion channel. The Company’s lead oncology drug candidate, SOR-C13, is the first highly specific TRPV6 inhibitor to be identified and advanced to clinical trials.
To read more, click here! |
|
|
Hear from our exclusive legal partner, Torys LLP, on the top legal considerations for life science companies.
What you need to know about IP
In our inaugural Torys Tips, Eileen McMahon and Karen Townsend share some key factors you should keep in mind when building an IP strategy.
Read more here! |
|
|
|
|
A tremendous amount of innovation occurs in academia and the medical industry, where medical devices are conceptualized and developed to improve the lives of populations and produce favourable clinical and economic outcomes.
Regulatory approval, reimbursement, and market adoption of medical devices involve a variety of stakeholders, each with unique requirements. All groups expect some degree of clinical and at times economic evidence (here in referred to as clinical evidence) to aid in their decision making.The level and extent of clinical evidence (completed and published studies) required for regulatory clearance and approval of Medical Devices can vary based on factors such as the risk level and regulatory class of the device, existence of similar products with established safety and performance profile on the market, and the nature of the disease state addressed by the device. Read more here! |
|
|
|
|
|
.png)
.png)
.png)
